Thermo Fisher Scientific (NYSE:TMO) stock gains as company beats Q2 2025 forecasts with $10.9B revenue, driven by Life ...

Shares of the medical equipment maker were up 2.5% in premarket trading. The company joins peers such as Danaher in beating ...

Thermo Fisher Scientific posted better-than-expected profit and revenue in its latest quarter.

Thermo Fisher Scientific's second quarter of 2025 demonstrated a 3% revenue increase to $10.85 billion, slightly surpassing expectations.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025.

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and ...

The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.